Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 7/2011

01-07-2011 | Clinical Research

The Effects of Biliopancreatic Diversion on Type 2 Diabetes Mellitus in Patients with Mild Obesity (BMI 30–35 kg/m2) and Simple Overweight (BMI 25–30 kg/m2): A Prospective Controlled Study

Authors: Nicola Scopinaro, Giovanni F. Adami, Francesco S. Papadia, Giovanni Camerini, Flavia Carlini, Lucia Briatore, Gabriele D’Alessandro, Corrado Parodi, Andrea Weiss, Gabriella Andraghetti, Mariafrancesca Catalano, Renzo Cordera

Published in: Obesity Surgery | Issue 7/2011

Login to get access

Abstract

Background

Beneficial effects of BPD on T2DM in BMI >35 kg/m2 patients are far better than those in patients with BMI 25–35. This study was aimed at investigating if a similar difference exists between patients with mild obesity (OB, BMI 30–35) or simple overweight (OW, BMI 25–30).

Methods

Fifteen OB (six M) and 15 OW (13 M), diabetic for ≥3 years, with HbA1c ≥7.5% despite medical therapy, underwent BPD. OB/OW: age 55.1 ± 8.0/57.8 ± 6.7 years, BMI 33.1 ± 1.5/28.0 ± 1.3 kg/m2, diabetes duration 11.6 ± 8.0/11.1 ± 6.1 years, insulin therapy 4/8 p. FSG and HbA1c were determined preoperatively and up to 2 years. Insulin resistance and beta-cell function were explored by means of HOMA-IR and IVGTT (AIR). Thirty-eight diabetic patients on medical therapy served as controls.

Results

Mean BMI stabilized around 27 since the 4th month in OB, and 24 since 1st month in OW. FSG in OB/OW preop, 1, 12, 24 months: 234 ± 76/206 ± 62 mg/dL, 154 ± 49/176 ± 75, 131 ± 32/167 ± 48, 134 ± 41/154 ± 41 (cross-sectional n.s. at all times); HbA1c: 9.5 ± 1.6/9.1 ± 1.3, 7.3 ± 1.1/7.3 ± 1.2, 5.9 ± 0.6/7.1 ± 1.1 (p < 0.01), 5.9 ± 0.9/6.9 ± 1.1 (p < 0.01). HOMA-IR, preoperatively 10.7 ± 5.8/7.5 ± 5.4, went below 3.0 at 1 month and remained such until 2 years in both groups. AIR, preoperatively 1.11 ± 3.17/1.27 ± 2.68 μIU/mL, in OB significantly increased at 4 months to 7.63 ± 5.79, maintained up to 2 years with 6.95 ± 3.19, whereas in OW, statistical significance was reached only at 2 years with 5.02 ± 4.87.

Conclusions

Significantly different BPD effect, thus biological severity of T2DM, also exists between mildly obese and simply overweight patients. The rise of AIR allows hoping that an increase of beta-cell mass may occur in the long run.
ClinicalTrials.gov Identifier: NCT00996294
Literature
1.
Scopinaro N, Gianetta E, Civalleri D, et al. Bilio-pancreatic Bypass for Obesity: II. Initial Experience in Man. Br J Surg. 1979;66:618–20.PubMedCrossRef
2.
Scopinaro N, Gianetta E, Adami GF, et al. Biliopancreatic Diversion for Obesity at Eighteen Years. Surgery. 1996;119:261–8.PubMedCrossRef
3.
Scopinaro N, Adami GF, Marinari GM, et al. Biliopancreatic Diversion. World J Surg. 1998;22:936–46.PubMedCrossRef
4.
Scopinaro N, Gianetta E, Friedman D, et al. Evolution of Biliopancreatic Bypass. Clin Nutr. 1986;5(suppl):137–46.
5.
Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a Systematic Review and Meta-analysis. JAMA. 2004;292:1724–37.PubMedCrossRef
6.
Buchwald H, Estok R, Fahrbach K, et al. Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis. Am J Med. 2009;122:248–56.PubMedCrossRef
7.
Scopinaro N, Marinari GM, Camerini GB, et al. Specific Effects of Biliopancreatic Diversion on the Major Components of Metabolic Syndrome: A Long-term Follow-up Study. Diabetes Care. 2005;28:2406–11.PubMedCrossRef
8.
Scopinaro N, Papadia F, Camerini G, et al. A Comparison of a Personal Series of Biliopancreatic Diversion and Literature Data on Gastric Bypass Help to Explain the Mechanisms of Resolution of Type 2 Diabetes by the Two Operations. Obes Surg. 2008;18:1035–8.PubMedCrossRef
9.
McAuley K, Mann J. Thematic Review Series: Patient Oriented Research. Nutritional Determinants of Insulin Resistance. J Lipid Res. 2006;47:1668–76.PubMedCrossRef
10.
Brandi LS, Santoro D, Natali A, et al. Insulin Resistance of Stress: Sites and Mechanisms. Clin Sci (Lond). 1993;85:525–35.
11.
Thorell A, Nygren J, Ljungqvist O. Insulin Resistance: A Marker of Surgical Stress. Curr Opin Clin Nutr Metab Care. 1999;2:69–78.PubMedCrossRef
12.
Adami GF, Cordera R, Camerini G, et al. Recovery of Insulin Sensitivity in Obese Patients at Short Term after Biliopancreatic Diversion. J Surg Res. 2003;113:217–21.PubMedCrossRef
13.
Wickremesekera K, Miller G, Naotunne TD, et al. Loss of Insulin Resistance after Roux-en-Y Gastric Bypass Surgery: A Time Course Study. Obes Surg. 2005;15:474–81.PubMedCrossRef
14.
Briatore L, Salani B, Andraghetti G, et al. Restoration of Acute Insulin Response in T2DM Subjects 1 Month after Biliopancreatic Diversion. Obesity. 2008;16:77–81.PubMedCrossRef
15.
Polyzogopoulou EV, Kalfarentzos F, Vagenakis AG, et al. Restoration of Euglycemia and Normal Acute Insulin Response to Glucose in Obese Subjects with Type 2 Diabetes Following Bariatric Surgery. Diabetes. 2003;52:1098–103.PubMedCrossRef
16.
Adami GF, Murelli F, Briatore L, et al. Pregnancy in Formerly Type 2 Diabetes Obese Women Following Biliopancreatic Diversion for Obesity. Obes Surg. 2008;18:1109–11.PubMedCrossRef
17.
Doyle ME, Egan JM. Mechanisms of Action of Glucagone-like Peptide 1 in the Pancreas. Pharmacol Ther. 2007;113:546–93.PubMedCrossRef
18.
Xu G, Stoffers DA, Habener JF, et al. Exendin-4 Stimulates Both Beta-cell Replication and Neogenesis, Resulting in Increased Beta-cell Mass. Diabetes. 1999;48:2270–6.PubMedCrossRef
19.
Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like Peptide 1 Inhibits Cell Apoptosis and Improve Glucose Responsiveness of Freshly Isolated Human Islets. Endocrinology. 2003;144:5149–58.PubMedCrossRef
20.
Borg CM, le Roux CW, Ghatei MA, et al. Biliopancreatic Diversion in Rats is Associated with Intestinal Hypertrophy and with Increased GLP-1, GLP-2 and PYY levels. Obes Surg. 2007;17:1193–8.PubMedCrossRef
21.
Valverde I, Puente J, Martín-Duce A, et al. Changes in Glucagon-like Peptide-1 (GLP-1) Secretion after Biliopancreatic Diversion or Vertical Banded Gastroplasty in Obese Subjects. Obes Surg. 2005;15:387–97.PubMedCrossRef
22.
Guidone C, Manco M, Valera-Mora E, et al. Mechanisms of Recovery from Type 2 Diabetes after Malabsorptive Bariatric Surgery. Diabetes. 2006;55:2025–31.PubMedCrossRef
23.
Scopinaro N, Adami GF, Papadia FS, et al. Effects of biliopancreatic diversion on type 2 diabetes in patients with BMI 25–35. Ann Surg. 2011;253:699–703.PubMedCrossRef
24.
Scopinaro N, Marinari GM, Camerini G, et al. Energy and Nitrogen Absorption after Biliopancreatic Diversion. Obes Surg. 2000;10:436–41.PubMedCrossRef
25.
International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32:1327–34.
26.
Beil U, Crouse JR, Einarsson K, et al. Effects of Interruption of the Enterohepatic Circulation of Bile Acids on the Transport of Very Low Density-lipoprotein Triglycerides. Metabolism. 1982;31:438–44.PubMedCrossRef
27.
Ast M, Frishman WH. Bile Acid Sequestrants. J Clin Pharmacol. 1990;30:99–106.PubMed
Metadata
Title
The Effects of Biliopancreatic Diversion on Type 2 Diabetes Mellitus in Patients with Mild Obesity (BMI 30–35 kg/m2) and Simple Overweight (BMI 25–30 kg/m2): A Prospective Controlled Study
Authors
Nicola Scopinaro
Giovanni F. Adami
Francesco S. Papadia
Giovanni Camerini
Flavia Carlini
Lucia Briatore
Gabriele D’Alessandro
Corrado Parodi
Andrea Weiss
Gabriella Andraghetti
Mariafrancesca Catalano
Renzo Cordera
Publication date
01-07-2011
Publisher
Springer-Verlag
Published in
Obesity Surgery / Issue 7/2011
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-011-0407-0

Other articles of this Issue 7/2011

Obesity Surgery 7/2011 Go to the issue

Clinical Research

Improvement of Insulin Resistance and Reduction of Cardiovascular Risk Among Obese Patients with Type 2 Diabetes with the Duodenojejunal Bypass Liner

Clinical Research

Effects of Sleeve Gastrectomy and Medical Treatment for Obesity on Glucagon-like Peptide 1 Levels and Glucose Homeostasis in Non-diabetic Subjects

Letter to the Editor

Magnesium Status After Gastric Bypass Surgery

Clinical Research

Diabetes Remission and Insulin Secretion After Gastric Bypass in Patients with Body Mass Index <35 kg/m2

Clinical Report

Effects of A-Line Autoregression Index (AAI) Monitoring on Recovery After Sevoflurane Anesthesia for Bariatric Surgery

Clinical Research

The Use of an Improved Intragastric Balloon Technique to Reduce Weight in Pre-obese Patients—Preliminary Results